Er Therapeutics Market Capitalization vs. Current Liabilities
| PNGM Stock | USD 0.0001 0.00 0.000003% |
For Er Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Er Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Er Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Er Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Er Therapeutics over time as well as its relative position and ranking within its peers.
PNGM |
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Er Therapeutics Current Liabilities vs. Market Capitalization Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Er Therapeutics's current stock value. Our valuation model uses many indicators to compare Er Therapeutics value to that of its competitors to determine the firm's financial worth. Er Therapeutics is regarded second in market capitalization category among its peers. It is considered to be number one stock in current liabilities category among its peers creating about 1.94 of Current Liabilities per Market Capitalization. As of the 26th of December 2024, Total Current Liabilities is likely to drop to about 308.4 K. Comparative valuation analysis is a catch-all technique that is used if you cannot value Er Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.PNGM Market Capitalization vs. Competition
Er Therapeutics is regarded second in market capitalization category among its peers. Market capitalization of Materials industry is at this time estimated at about 120.14 Billion. Er Therapeutics adds roughly 332,107 in market capitalization claiming only tiny portion of all equities under Materials industry.
PNGM Current Liabilities vs. Market Capitalization
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Er Therapeutics |
| = | 332.11 K |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Er Therapeutics |
| = | 645 K |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
PNGM Current Liabilities Comparison
Er Therapeutics is currently under evaluation in current liabilities category among its peers.
Er Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Er Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Er Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Er Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Er Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -280.2 K | -294.2 K | |
| Net Loss | -384.3 K | -403.5 K | |
| Income Before Tax | -384.3 K | -403.5 K | |
| Total Other Income Expense Net | -104.1 K | -98.9 K | |
| Net Loss | -384.3 K | -403.5 K | |
| Net Loss | -384.3 K | -403.5 K | |
| Change To Netincome | 123.6 K | 129.8 K |
PNGM Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Er Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Er Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Er Therapeutics' important profitability drivers and their relationship over time.
Use Er Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Er Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Er Therapeutics will appreciate offsetting losses from the drop in the long position's value.Er Therapeutics Pair Trading
Er Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Er Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Er Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Er Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Er Therapeutics to buy it.
The correlation of Er Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Er Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Er Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Er Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Er Therapeutics position
In addition to having Er Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Management Thematic Idea Now
Health Management
Major hospitals and healthcare providers. The Health Management theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Management Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
To fully project Er Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Er Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Er Therapeutics' income statement, its balance sheet, and the statement of cash flows.